EP0228125B1 - Novel derivatives of [[4-[4-(4-phenyl-1-piperazinyl)phenoxymethyl]-1,3-dioxolan-2-yl]methyl]-1H-imidazoles and 1H-1,2,4-triazoles - Google Patents

Novel derivatives of [[4-[4-(4-phenyl-1-piperazinyl)phenoxymethyl]-1,3-dioxolan-2-yl]methyl]-1H-imidazoles and 1H-1,2,4-triazoles Download PDF

Info

Publication number
EP0228125B1
EP0228125B1 EP86202230A EP86202230A EP0228125B1 EP 0228125 B1 EP0228125 B1 EP 0228125B1 EP 86202230 A EP86202230 A EP 86202230A EP 86202230 A EP86202230 A EP 86202230A EP 0228125 B1 EP0228125 B1 EP 0228125B1
Authority
EP
European Patent Office
Prior art keywords
formula
phenyl
alkyl
parts
radical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP86202230A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP0228125A1 (en
Inventor
Jan Heeres
Leo Jacobus Jozef Backx
Jozef Bertha August Thijssen
Alfonsus Guilielms Knaeps
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Priority to AT86202230T priority Critical patent/ATE73799T1/de
Publication of EP0228125A1 publication Critical patent/EP0228125A1/en
Application granted granted Critical
Publication of EP0228125B1 publication Critical patent/EP0228125B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms

Definitions

  • EP-A-6,711 there are described a number of heterocyclic derivatives of (4-phenyl-1-piperazinyl-aryloxymethyl-1,3-dioxolan-2-yl)methyl-1 H -imidazoles and 1 H -1,2,4-triazoles wherein the 4-phenyl-1-piperazinyl moiety is substituted with a 2,4-dihydro-3H-1,2,4-triazol-3-one group being substituted with lower alkyl or aryllower alkyl.
  • the latter compounds are taught to possess anti-fungal and anti-bacterial properties.
  • the compounds of the present invention differ therefrom by the fact that they invariably contain a 4-phenyl-1-piperazinyl moiety in which the phenyl part is substituted with a five-membered heterocycle being substituted with particular radicals, among which C1 ⁇ 6alkyl substituted with oxo, thioxo or with one or two alkyloxy groups.
  • the present compounds differ pharmacologically from the art-compounds by their favourable anti-microbial properties, in particular their beneficial topical activity against candidosis and their increased solubility.
  • This invention is concerned with 1 H -imidazoles and 1 H -1,2,4-triazoles having the formula the pharmaceutically acceptable acid-addition salts and the stereochemically isomeric forms thereof, wherein Q is N or CH; Ar is aryl; R is hydrogen or C1 ⁇ 6 alkyl; and Y-R1 is a radical having the formula or a radical having the formula wherein R1 is tetrahydrofuranylC1 ⁇ 6 alkyl; or C1 ⁇ 6 alkyl, C3 ⁇ 6 cycloalkyl, arylC1 ⁇ 6 alkyl or (C3 ⁇ 6 cycloalkyl)C1 ⁇ 6 alkyl all substituted on the C1 ⁇ 6 alkyl and/or C3 ⁇ 6 cycloalkyl moiety with oxo, thioxo or with one or two radicals of formula -Z-R1 ⁇ a; said Z being O or S; said R1 ⁇ a being hydrogen, C 1-6 alkyl, aryl, C 3-6
  • halo is generic to fluoro, chloro, bromo and iodo
  • C 1-6 alkyl is meant to include straight and branched hydrocarbon radicals having from l to 6 carbon atoms such as for example, methyl, ethyl, l-methylethyl, l,l-dimethylethyl, propyl, l-methylpropyl, 2-methylpropyl, butyl, pentyl, hexyl and the like;
  • C 3-6 cycloalkyl embraces cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
  • the compounds of formula (I) may contain in their structure a tautomeric system and consequently these compounds can be present in each of their tautomeric forms.
  • Preferred compounds within the invention are those wherein Y-R1 is a radical of formula (a) or (b), wherein X, A, B, A′, B′ and R1 are as described hereinabove, provided that A′ and B′, taken together, do not form a radical of formula (c) or (d).
  • Particularly preferred compounds within the invention are those preferred compounds wherein Y-R1 is a radical of formula (a).
  • Especially preferred compounds within the invention are those more particularly preferred compounds wherein R1 is C 3-6 cycloalkyl substituted with oxo or hydroxy, or C 1-6 alkyl or arylC 1-6 alkyl both substituted on the C 1-6 alkyl moiety with oxo or with one or two hydroxy or C 1-6 alkyloxy radicals.
  • Ar is phenyl substituted with two halo atoms;
  • R is hydrogen;
  • A is C(CH3)2 or CH2,
  • R1 is C 1-6 alkyl substituted with oxo or hydroxy.
  • the compounds of formula (I) can be prepared by N -alkylating an intermediate of formula (II) with an appropriate reactive ester of formula (III).
  • R1 has the previously defined meaning and W is a reactive ester residue such as, for example, halo, preferably chloro, bromo or iodo, or a sulfonyloxy group such as, for example, methylsulfonyloxy, 2-naphtalenesulfonyloxy or 4-methylphenylsulfonyloxy and the like.
  • Suitable reaction-inert solvent are, for example, an aromatic hydrocarbon, e.g., benzene, methylbenzene, dimethylbenzene, and the like; a lower alkanol, e.g.
  • methanol, ethanol, l-butanol and the like e.g., 2-propanone, 4-methyl-2-pentanone and the like; an ether, e.g., l,4-dioxane, l,l′-oxybisethane, tetrahydrofuran and the like; a polar aprotic solvent, e.g., N , N -dimethylformamide (DMF), N , N -dimethylacetamide (DMA), dimethyl sulfoxide (DMSO), nitrobenzene, l-methyl-2-pyrrolidinone, and the like.
  • a ketone e.g., 2-propanone, 4-methyl-2-pentanone and the like
  • an ether e.g., l,4-dioxane, l,l′-oxybisethane, tetrahydrofuran and the like
  • a polar aprotic solvent e
  • An aromatic hydrocarbon e.g., dichloromethane, trichloromethane and the like may advantageously be employed when (III) is in the form of a reactive anhydride.
  • an appropriate base such as, for example, an alkali or an earth alkaline metal carbonate, hydrogen carbonate, hydroxide or hydride, e.g., sodium hydroxide, potassium hydroxide, potassium carbonate, sodium hydride and the like or an organic base such as, for example, N , N -dimethyl-4-pyridinamine, N , N -diethylethanamine or N -(l-methylethyl)-2-propanamine may be suited to pick up the acid which is liberated during the course of the reaction.
  • the compounds of formula (I) can also be prepared by O -alkylating an appropriately substituted phenol of formula (V) with a reactive ester of formula (IV).
  • W has the previously described meaning.
  • reaction of (IV) with (V) is carried out under art-known conditions of performing O -alkylations with reactive esters.
  • the O -alkylation reaction is conveniently conducted in a suitable reaction-inert solvent or a mixture of such solvents.
  • Suitable reaction-inert solvents are, for example, an aromatic hydrocarbon, e.g., benzene, methylbenzene, dimethylbenzene, and the like; a lower alkanol, e.g., methanol, ethanol, l-butanol and the like; a ketone, e.g., 2-propanone, 4-methyl-2-pentanone and the like; an ether, e.g., l,4-dioxane, l,l′-oxybisethane, tetrahydrofuran and the like; a polar aprotic solvent, e.g., N , N -dimethylformamide (DMF), N , N -d
  • An appropriate base such as, for example, an alkali or an earth alkaline metal carbonate, hydrogen carbonate, hydroxide, alkoxide or hydride, e.g., sodium carbonate, sodium hydrogen carbonate, potassium carbonate, sodium hydroxide, sodium methoxide, sodium hydride and the like, or an organic base such as, for example, a tertiary amine, e.g., N , N -diethylethanamine, N -(l-methylethyl)-2-propanamine, 4-ethylmorpholine, pyridine, quinoline, l H -imidazole, l H -l,2,4-triazole and the like, may be utilized to pick up the acid which is liberated during the course of the reaction.
  • an alkali or an earth alkaline metal carbonate hydrogen carbonate, hydroxide, alkoxide or hydride
  • the water, the alcohol or the acid which is liberated during the course of the reaction may preferably be removed from the reaction mixture by azeotropical destillation. It may be advantageous previously to convert the substituted phenol (V) into a metal salt thereof, preferably the sodium salt, in the usual manner, e.g., by the reaction of (V) with a metal base such as sodium hydride, sodium hydroxide and the like, and to use thereafter said metal salt in the reaction with (IV).
  • the said O -alkylation may alternatively be carried out following art-known conditions of a phase transfer reaction, in which a phase transfer catalyst catalyses the organic phase-aqueous phase reaction by extracting the ions out of the aqueous phase into the bulk organic phase where reaction can ensue.
  • Suitable phase transfer catalysts are organic-soluble, partially water soluble catalysts, e.g., trialkylphenylmethylammonium or tetraalkylammonium halides, hydroxides and hydrogen sulfates. Somewhat elevated temperatures may be appropriate to enhance the reaction rate of the said O -alkylation and most preferably said reaction is carried out at a temperature from about 80°C to about l30°C.
  • the compounds of formula (I) may also generally be prepared by first O -alkylating a substituted phenol of formula (V) with a dioxolan of formula (VI), in which W and W′ independently have the meaning of W in the formula (III), provided that the leaving group capacity of W exceeds that of W′, thus preparing an intermediate of formula (VII), and subsequently reacting said intermediate of formula (VII) with an azole of formula (VIII).
  • the reaction of (VII) with (VIII) may be conducted in an appropriate organic solvent such as, for example, N , N -dimethylformamide or N , N -dimethylacetamide and the like. It may be advantageous to use an excess of azole or to add to the reaction mixture an appropriate base such as, for example, an alkali or an earth alkaline metal carbonate or hydrogen carbonate. It may particularly be advantageous previously to convert the azole, (VIII), into a metal salt from thereof by treatment with an appropriate metallating agent such as, for example, a metal alkoxide or a metal hydride. In some circumstances the addition of a iodide salt, preferably an alkali metal iodide, is appropriate. Somewhat elevated temperatures may enhance the rate of the reaction.
  • an appropriate organic solvent such as, for example, N , N -dimethylformamide or N , N -dimethylacetamide and the like. It may be advantageous to use an excess of azole or to add to the
  • the compounds of formula (I) may also be prepared by reacting a ketone of formula (IX) with a l,2-diol of formula (X), or the corresponding epoxide form thereof, in a suitable ketalizing medium.
  • Suitable ketalizing media are mixtures containing an appropriate amount of one or more acids in a suitable solvent such as, for example, an alcohol or an aliphatic-, alicyclic- or aromatic hydrocarbon and the like. Acids which are preferably used in the said ketalizing media are relatively strong, anhydrous acids, having a pKa-value inferior to 4.
  • the compounds of formula (I) may also be prepared by cyclizing an intermediate of formula (XI) with an amine of formula (XII) or by cyclizing an amine of formula (XIII) with an intermediate of formula (XIV).
  • the reaction is carried out by stirring the reactants in the presence of an appropriate polar solvent, e.g., water, in admixture with an appropriate water-miscible organic solvent such as, for example, 2-propanol, 2-propanone and the like, preferably at an elevated temperature.
  • an appropriate base such as, for example, an alkali or an earth alkaline metal carbonate or hydrogen carbonate may be suited to pick up the acid which is liberated during the course of the reaction.
  • an appropriate iodide salt e.g., sodium or potassium iodide may be added as a reaction promotor.
  • the compounds of formula (I) can also be prepared by N -alkylating a piperazine of formula (XV) with an appropriately substituted benzene of formula (XVI) or by N -alkylating a piperazine of formula (XVIII) with a benzene of formula (XVII).
  • Said N -alkylation reaction may be carried out in the usual manner, e.g., by stirring the reactants, preferably at somewhat elevated temperatures in an appropriate organic solvent such as, for example, dimethylsulfoxide, N , N -dimethylformamide and the like, in the presence of an appropriate base such as, for example, an alkali metal hydride or carbonate.
  • an appropriate organic solvent such as, for example, dimethylsulfoxide, N , N -dimethylformamide and the like
  • an appropriate base such as, for example, an alkali metal hydride or carbonate.
  • the compounds of formula (I) may also be prepared by cyclizing an intermediate of formula Said L in formula (XIX) being a radical -A-B-L′ or -A′-B′-L′ wherein L′ is an appropriate leaving group.
  • the said cyclization reaction can generally be conducted in a suitable reaction-inert solvent such as, for example, an alcohol, e.g., butanol and the like, an ether, e.g., tetrahydrofuran, l,4-dioxane and the like.
  • a suitable reaction-inert solvent such as, for example, an alcohol, e.g., butanol and the like, an ether, e.g., tetrahydrofuran, l,4-dioxane and the like.
  • a suitable reaction-inert solvent such as, for example, an alcohol, e.g., butanol and the like, an ether, e.g., tetrahydrofuran, l,4-dioxane and the like.
  • the reaction may be conducted at room temperature, somewhat elevated temperatures are appropriate to enhance the rate of the reaction.
  • the reaction is conducted at the reflux temperature of the reaction mixture.
  • the compounds of formula (I), wherein Y-R1 is a radical of formula (b) wherein X is NR2, said compounds being represented by the formula (I-b) may be prepared by a cyclodesulfurization reaction of an intermediate of formula (XX).
  • Said cyclodesulfurization reaction may be carried out by the reaction of (XX) with an appropriate alkyl halide, in an appropriate reaction-inert organic solvent, e.g., a lower alkanol. Otherwise, the cyclodesulfurization reaction may be carried out by the reaction of (XX) with an appropriate metal oxide or salt in an appropriate solvent according to art-known procedures. In certain instances it may be appropriate to supplement the reaction mixture with a small amount of sulfur. Even so methanediimines, especially N , N -methanetetraylbis-[cyclohexanamine] may be used as cyclodesulfurizing agents.
  • Compounds of formula (I) having a hydroxy function respectively a mercapto function may be O -alkylated respectively S -alkylated with an appropriate reagent following art-known alkylation procedures.
  • a (tetrahydro-2 H -pyran-2-yl)oxy group may conveniently be converted to a hydroxy group following art-known procedures such as, for example, by hydrolysis in acidic aqueous medium.
  • the compounds of formula (I) wherein R1 is substituted with oxo, thioxo or with two hydroxy or mercapto radicals may be acetalized or ketalized to yield the corresponding compounds wherein R1 is geminally substituted with two -Z-R1 ⁇ a radicals, or wherein R1 is substituted with a bivalent radical such as, for example, -Z-C(CH3)2-Z- or -Z-CH2-CH2-Z-. Or conversely, the latter compounds may be deketalized or deacetalized to yield the corresponding oxo, thioxo, or dihydroxy or dimercapto compounds.
  • Said acetalization of ketalization reaction may conveniently be conducted following art-known procedures such as, for example by reacting the starting material with an alcohol, diol, thiol or dithiol in the presence of an appropriate acid, preferably with removal of the reaction products which are formed during the course of the reaction.
  • Said deketalization of deacetalization may also be conducted following procedures widely known in the art such as, for example, by reacting the starting materials in an acidic aqueous medium.
  • l H -imidazole- and l H -l,2,4-triazole-derivatives of formula (I), obtained in base form in the foregoing preparations, may be converted to their therapeutically active non-toxic acid addition salt forms by treatment with appropriate acids, such as, for example, inorganic acids, such as hydrohalic acid, e.g.
  • the salts are in turn converted to the corresponding free bases in the usual manner, e.g., by reaction with
  • the reactive esters of formula (IV) can be prepared along a sequence of reactions described in U.S. Patent No. 4,267,l79 and in J. Med. Chem., 22 (8), l003-5 (l979).
  • Starting materials of formula (IX) can conveniently be prepared by reacting l-Ar-2-haloethanone with an azole, (VIII), in an inert solvent, if appropriate in the presence of a base.
  • the compounds of formula (I), the pharmaceutically acceptable acid addition salts and stereochemically isomeric forms thereof are useful agents due to their favourable anti-microbial properties and particularly to their increased solubility.
  • the strong anti-microbial activity of the compounds of formula (I) can be demonstrated for example, in the "Oral treatment of vaginal candidosis in rats" test or in the “Topical treatment of vaginal candidosis in rats” test illustrating the useful anti-microbial activity of the compounds of the present invention.
  • the subject compounds may be formulated into various pharmaceutical forms for administration purposes.
  • compositions of this invention an effective amount of the particular compound, in base or acid-addition salt form, as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable carrier, which carrier may take a wide variety of forms depending on the form of preparation desired for administration.
  • a pharmaceutically acceptable carrier which carrier may take a wide variety of forms depending on the form of preparation desired for administration.
  • These pharmaceutical compositions are desirably in unitary dosage form suitable, preferably, for administration orally, rectally or by parenteral injection.
  • any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs and solutions; or solid carriers such as starches, sugars, kaolin, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed.
  • the carrier will usually comprise sterile water, at least in large part, though other ingredients, for example, to aid solubility, may be included.
  • Injectable solutions may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution. Injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed.
  • the carrier optionally comprises a penetration enhancing agent and/or a suitable wetting agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not cause a significant deletorious effect to the skin. Said additives may facilitate the administration to the skin and/or may be helpful for preparing the desired compositions.
  • These compositions may be administered in various ways, e.g., as a transdermal patch, as a spot-on, as an ointment. Acid addition salts of (I) due to their increased water solubility over the corresponding base form, are obviously more suitable in the preparation of aqueous compositions.
  • Dosage unit form as used in the specification and claims herein refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
  • dosage unit forms are tablets (including scored or coated tablets), capsules, pills, powder packets, wafers, injectable solutions or suspensions, teaspoonfuls, tablespoonfuls and the like, and segregated multiples thereof.
  • the compounds of formula (I), the pharmaceutically acceptable acid addition salts and stereochemically isomeric forms thereof are useful agents in combatting fungi and bacteria.
  • said compounds are found to be highly active against a wide variety of fungi such as, for example, Microsporum canis , Pityrosporum ovale , Ctenomyces mentagrophytes , Trichophyton rubrum , Phialophora verrucosa , Cryptococcus neoformans , Candida tropicalis , Candida albicans , Mucor species , Aspergillus fumigatus , Sporotricum schenckii and Saprolegnia species , and against bacteria such as, for example, Erysipelotrix insidiosa , Staphylococci such as Staphylococcus hemolyticus and Streptococci such as Streptococcus pyogenes .
  • the compounds of this are found to be highly active against a wide variety of fungi such as
  • an effective amount would be from 0.0l mg/kg to 50 mg/kg body weight, and more preferably from 0.05 mg/kg to 20 mg/kg body weight.
  • the product was extracted with dichloromethane. The extract was subsequently washed with water, dried, filtered and evaporated. The residue was purified by column chromatography over silica gel using a mixture of trichloromethane and methanol (99:l by volume) as eluent. The pure fractions were collected and the eluent was evaporated. The residue was crystallized from a mixture of 2-propanone and 2,2′-oxybispropane.
  • the product was extracted with dichloromethane. The extract was subsequently washed with water, dried, filtered and evaporated. The residue was purified by filtration over silica gel using a mixture of trichloromethane and methanol (99.5:0.5 by volume) as eluent.
  • the product was extracted twice with dichloromethane. The combined extracts were washed with water, dried, filtered and evaporated in vacuo. The residue was taken up in methylbenzene and the whole was evaporated again. The residue was purified by column chromatography over silica gel using a mixture of trichloromethane and methanol (98:2 by volume) as eluent. The pure fractions were collected and the eluent was evaporated. The residue was triturated in methanol.
  • the aqueous layer was extracted with ethylacetate.
  • the extract was combined with the organic layer, which was set aside.
  • the organic layer was washed with water, dried, filtered and evaporated.
  • the residue was purified by column chromatography over silica gel using a mixture of trichloromethane and methanol (99:l by volume) as eluent. The pure fractions were collected and the eluent was evaporated. The residue was crystallized from ethanol.
  • the organic layer was purified by column chromatography over silica gel using a mixture of trichloromethane and methanol (99:l by volume) as eluent. The pure fractions were collected and the eluent was evaporated. The residue was crystallized from 2-propanol.
  • the pH of the solution was adjusted to 9 ⁇ l0 with potassium carbonate.
  • the product was crystallized, filtered off and taken up in dichloromethane.
  • the organic layer was dried, filtered and evaporated in vacuo. The residue was triturated in methanol.
  • the reaction mixture was acidified with concentrated hydrochloric acid to pH 2 and the whole was stirred for l hour at room temperature.
  • the reaction mixture was diluted with water and treated with potassium carbonate to pH 9 ⁇ l0.
  • the crystallized product was filtered off and dissolved in dichloromethane.
  • the organic layer was dried (in the presence of activated charcoal), filtered and evaporated in vacuo. The residue was stirred in methanol.
  • the reaction mixture was poured into a mixture of potassium carbonate and crushed ice.
  • the product was extracted with dichloromethane.
  • the extract was washed with a dilute sodium hydroxide solution, dried, filtered and evaporated.
  • the residue was purified twice by column chromatography over silica gel using a mixture of trichloromethane and methanol (99.5:0.5 by volume) as eluent.
  • the pure fractions were collected and the eluent was evaporated.
  • the residue was triturated in ethyl acetate.
  • mice Female Wistar rats of ⁇ l00 g body weight were used. They were ovariectomized and hysterectomized and after three weeks of recovery, l00 ⁇ g of oestradiol undecylate in sesame oil was given subcutaneously once a week for 3 consecutive weeks. The thus induced pseudo-oestrus was controlled by microscopic examination of vaginal smears. Food and water were left available ad libitum. The rats were infected intravaginally with 8.l05 cells of Candida albicans , grown on Sabouraud broth for 48 hours at 37°C and diluted with saline.
  • the date of infection varies from day +25 to day +32 after surgical intervention, depending on the appearance of signs of induced pseudo-oestrus.
  • the drugs under investigation were administered orally once a day or topically twice a day for three consecutive days starting from the third day after infection. For each experiment there were placebo treated controls.
  • the results were assessed by taking vaginal smears with sterile swabs on several days after the infection. The swabs were put into Sabouraud broth in petri-dishes and incubated for 48 hours at 37°C. If no growth of Candida albicans occurs, i.e., when the animals were negative at the end of the experiment, this was due to drug administration because it never happens in placebo-treated controls.
  • the first column in the Table I gives the lowest oral dose in mg/kg of the drug under investigation which is found active at the 14th day after infection.
  • the second column in the Table I gives the lowest concentration of the drug under investigation which is found active at the 7th day after the last topical administration of the drug.
  • compositions in dosage unit form suitable for systemic administration to animal and human subjects in accordance with the instant invention.
  • Active ingredient as used throughout these examples relates to a compound of formula (I) or a pharmaceutically acceptable acid addition salt thereof.
  • a mixture of l00 g of the A.I., 570 g lactose and 200 g starch was mixed well and thereafter humidified with a solution of 5 g sodium dodecyl sulfate and l0 g polyvinylpyrrolidone (Kollidon-K 90®) in about 200 ml of water.
  • the wet powder mixture was sieved, dried and sieved again.
  • the whole was mixed well and compressed into tablets, giving l0.000 tablets, each containing l0 mg of the active ingredient.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EP86202230A 1985-12-23 1986-12-10 Novel derivatives of [[4-[4-(4-phenyl-1-piperazinyl)phenoxymethyl]-1,3-dioxolan-2-yl]methyl]-1H-imidazoles and 1H-1,2,4-triazoles Expired - Lifetime EP0228125B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AT86202230T ATE73799T1 (de) 1985-12-23 1986-12-10 Derivate des ((4-(4-(4-phenyl-1piperazinyl)phenoxymethyl>-1,3-dioxolan2yl>methyl>-1h-imidazol und 1h-1,2,4-triazol.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81267085A 1985-12-23 1985-12-23
US812670 1985-12-23

Publications (2)

Publication Number Publication Date
EP0228125A1 EP0228125A1 (en) 1987-07-08
EP0228125B1 true EP0228125B1 (en) 1992-03-18

Family

ID=25210297

Family Applications (1)

Application Number Title Priority Date Filing Date
EP86202230A Expired - Lifetime EP0228125B1 (en) 1985-12-23 1986-12-10 Novel derivatives of [[4-[4-(4-phenyl-1-piperazinyl)phenoxymethyl]-1,3-dioxolan-2-yl]methyl]-1H-imidazoles and 1H-1,2,4-triazoles

Country Status (18)

Country Link
EP (1) EP0228125B1 (en, 2012)
JP (2) JPH0749428B2 (en, 2012)
AT (1) ATE73799T1 (en, 2012)
AU (2) AU589726B2 (en, 2012)
CA (1) CA1292472C (en, 2012)
CY (1) CY1825A (en, 2012)
DE (1) DE3684431D1 (en, 2012)
DK (2) DK164167C (en, 2012)
ES (1) ES2032381T3 (en, 2012)
FI (1) FI88505C (en, 2012)
GR (1) GR3004114T3 (en, 2012)
HK (1) HK46295A (en, 2012)
IE (1) IE59564B1 (en, 2012)
IL (1) IL81054A (en, 2012)
NO (1) NO167917C (en, 2012)
NZ (1) NZ218553A (en, 2012)
PT (1) PT84007B (en, 2012)
ZA (1) ZA869637B (en, 2012)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9969720B2 (en) 2015-05-21 2018-05-15 Pulmocide Limited Compounds useful to treat mycoses
US10093659B2 (en) 2014-12-05 2018-10-09 Plumocide Limited Compound useful to treat mycoses

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ223799A (en) * 1987-03-25 1989-12-21 Janssen Pharmaceutica Nv Azolylmethyl-dioxolanylmethoxyphenyl-piperazinyl-phenyl-triazolones and antimicrobial compositions
CA1331757C (en) 1988-02-29 1994-08-30 Janssen Pharmaceutica Naamloze Vennootschap 5-lipoxygenase inhibiting 4-(4-phenyl-1-piperazinyl)phenols
GR1000330B (el) * 1988-07-01 1992-06-25 Janssen Pharmaceutica Nv Μεθοδος παρασκευης παραγωγων 2,4 διυδρο-3η-1,2,4-τριαζολ-3-ονης.
GR1000302B (el) * 1988-07-01 1992-05-12 Janssen Pharmaceutica Nv Μεθοδος παρασκευης παραγωγων 2,4-διυδρο-3η-1,2,4-τριαζολ-3-ονης.
GR1000298B (el) * 1988-07-01 1992-05-12 Janssen Pharmaceutica Nv Μεθοδος παρασκευης παραγωγων 2,4-διυδρο-3η-1,2,4-τριαζολ-3-ονης.
GR1000297B (el) * 1988-07-01 1992-05-12 Janssen Pharmaceutica Nv Μεθοδος παρασκευης παραγωγων 2,4-διυδρο-3η-1,2,4-τριαζολ-3-ονης.
GB8903592D0 (en) * 1989-02-16 1989-04-05 Boots Co Plc Therapeutic agents
NZ233502A (en) * 1989-06-09 1991-11-26 Janssen Pharmaceutica Nv 4-(1,2,4-triazole- or imidazole-phenyl-substituted) -1-(1,3-dioxolan-4-ylmethoxyphenyl) piperazine derivatives; preparatory processes: fungicidal and antiviral compositions
CA2076257A1 (en) * 1991-09-13 1993-03-14 Jan Heeres 4-¬4-¬4-(4-hydroxyphenyl)-1- piperazinyl|phenyl|-5-methyl-3h -1,2,4-triazol-3-one derivatives
TW279864B (en, 2012) * 1993-02-19 1996-07-01 Janssen Pharmaceutica Nv
HU225062B1 (en) * 1993-12-21 2006-05-29 Schering Corp Tetrahydrofuran derivatives with antifungal- effect, pharmaceutical compositions containing them and process for their preparation
CN1078210C (zh) * 1994-01-24 2002-01-23 詹森药业有限公司 水溶性吡咯系杀真菌剂
US5571811A (en) * 1994-07-12 1996-11-05 Janssen Pharmaceutica N.V. Sulfonamide derivatives of azolones
AU697744C (en) * 1994-10-27 2002-08-22 Elanco Animal Health Ireland Limited Apolipoprotein-B synthesis inhibitors
US5625064A (en) * 1995-04-19 1997-04-29 Schering Corporation Process for the preparation of triazolones
TW457240B (en) * 1995-04-20 2001-10-01 Janssen Pharmaceutica Nv Novel triazolones as apolipoprotein-B synthesis inhibitors
AU6257596A (en) * 1995-06-19 1997-01-15 Schering Corporation Hydroxyalkyl-substituted triazolones antifungals
AU773405B2 (en) * 1996-11-12 2004-05-27 Sepracor, Inc. Hydroxyitraconazole enantiomer mixtures
JP2001504121A (ja) * 1996-11-12 2001-03-27 セプラコール，インク． ２ｒ，４ｓ，ｒ，ｓ―および２ｓ，４ｒ，ｒ，ｓ―ヒドロキシイトラコナゾール―およびヒドロキシサパーコナゾール誘導体
TW593312B (en) * 1997-07-11 2004-06-21 Janssen Pharmaceutica Nv 2,4,4-trisubstituted-1,3-dioxolane antifungals
CN100343249C (zh) * 1997-07-11 2007-10-17 詹森药业有限公司 2,4,4－三取代的1,3－二氧环戊烷抗真菌剂
AU9592998A (en) * 1997-10-07 1999-04-27 Schering Corporation Crystalline antifungal glycine ester polymorph
CN1349540A (zh) * 1999-05-04 2002-05-15 詹森药业有限公司 抗真菌的醚类
KR100342383B1 (ko) * 1999-06-17 2002-12-06 한국화학연구원 이소옥사졸리딘 유도체, 그의 제조 방법 및 그를 포함하는 살균제 조성물
MX342850B (es) * 2010-05-19 2016-10-14 Sandoz Ag Proceso para la preparacion de triazolonas quirales.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4144346A (en) * 1977-01-31 1979-03-13 Janssen Pharmaceutica N.V. Novel 1-(1,3-dioxolan-2-ylmethyl)-1H-imidazoles
US4218458A (en) * 1978-06-23 1980-08-19 Janssen Pharmaceutica, N.V. Heterocyclic derivatives of (4-aryloxy-methyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles
US4619931A (en) * 1983-02-28 1986-10-28 Janssen Pharmaceutica, N.V. [[4-[4-(4-phenyl-1-piperazinyl)phenoxymethyl]-1,3-dioxolan-2-yl]methyl]-1H-imidazoles and 1H-1,2,4-triazoles

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10800762B2 (en) 2014-12-05 2020-10-13 Pulmocide Limited Compounds which are used in the preparation of the compound of formula (II)
US11661415B2 (en) 2014-12-05 2023-05-30 Pulmocide Limited Process for preparing a compound useful to treat mycoses
US10106531B2 (en) 2014-12-05 2018-10-23 Pulmocide Limited Compound useful to treat mycoses
US12269814B2 (en) 2014-12-05 2025-04-08 Pulmocide Limited Process for preparing a compound useful to treat mycoses
US10344022B2 (en) 2014-12-05 2019-07-09 Pulmocide Limited Compound useful to treat mycoses
US10450304B2 (en) 2014-12-05 2019-10-22 Pulmocide Limited Compound useful to treat mycoses
US10662179B2 (en) 2014-12-05 2020-05-26 Pulmocide Limited Process for preparing a compound useful to treat mycoses
US10487073B2 (en) 2014-12-05 2019-11-26 Pulmocide Limited Compounds which are used in the preparation of the compound of formula (I)
US10093659B2 (en) 2014-12-05 2018-10-09 Plumocide Limited Compound useful to treat mycoses
US11008307B2 (en) 2014-12-05 2021-05-18 Pulmocide Limited Compounds which are used in the preparation of the compound of formula (I)
US10858345B2 (en) 2014-12-05 2020-12-08 Pulmocide Limited Process for preparing a compound useful to treat mycoses
US9969720B2 (en) 2015-05-21 2018-05-15 Pulmocide Limited Compounds useful to treat mycoses
US10513511B2 (en) 2015-05-21 2019-12-24 Pulmocide Limited Aqueous suspension formulation comprising 4-(4-(4-(((3R,5R)-5-((1H-1,2,4-triazol-1-yl)methyl)-5-(2,4-difluoro-phenyl)tetrahydrofuran-3-yl)methoxy)-3-methylphenyl) or a pharmaceutically acceptable salt thereof
US10280155B2 (en) 2015-05-21 2019-05-07 Pulmocide Limited Process for preparing 4-(4-(4-(((3R,5R)-5-((1H-1,2,4-triazol-1-yl)methyl)-5-(2,4-difluoro-phenyl)tetrahydrofuran-3-yl)methoxy)-3-methylphenyl)piperazin-1-yl)-N-((1S,2S)-2-hydroxycyclohexyl) benzamide or a pharmaceutically acceptable salt thereof

Also Published As

Publication number Publication date
NO167917B (no) 1991-09-16
DK625586D0 (da) 1986-12-22
DK74691A (da) 1991-04-23
AU593736B2 (en) 1990-02-15
AU1607688A (en) 1988-08-04
IE863369L (en) 1987-06-23
NO865235L (no) 1987-06-24
DK74691D0 (da) 1991-04-23
NO167917C (no) 1991-12-27
IL81054A0 (en) 1987-03-31
DK167356B1 (da) 1993-10-18
DK625586A (da) 1987-06-24
FI88505B (fi) 1993-02-15
FI865257A0 (fi) 1986-12-22
AU589726B2 (en) 1989-10-19
FI88505C (fi) 1993-05-25
PT84007B (pt) 1989-06-30
CY1825A (en) 1995-12-01
ATE73799T1 (de) 1992-04-15
JPH07285963A (ja) 1995-10-31
CA1292472C (en) 1991-11-26
NZ218553A (en) 1990-06-26
DE3684431D1 (de) 1992-04-23
IL81054A (en) 1992-03-29
FI865257A7 (fi) 1987-06-24
JPS62158275A (ja) 1987-07-14
GR3004114T3 (en, 2012) 1993-03-31
IE59564B1 (en) 1994-03-09
ZA869637B (en) 1988-08-31
HK46295A (en) 1995-04-07
EP0228125A1 (en) 1987-07-08
JP2574656B2 (ja) 1997-01-22
PT84007A (en) 1987-01-01
NO865235D0 (no) 1986-12-22
AU6685386A (en) 1987-06-25
ES2032381T3 (es) 1993-02-16
DK164167C (da) 1992-10-12
JPH0749428B2 (ja) 1995-05-31
DK164167B (da) 1992-05-18

Similar Documents

Publication Publication Date Title
EP0228125B1 (en) Novel derivatives of [[4-[4-(4-phenyl-1-piperazinyl)phenoxymethyl]-1,3-dioxolan-2-yl]methyl]-1H-imidazoles and 1H-1,2,4-triazoles
US4791111A (en) [[4-[4-(4-phenyl-1-piperazinyl)phenoxymethyl]-1,3-dioxolan-2-yl]methyl]-1H-imidazoles and 1H-1,2,4-triazoles having anti-microbial properties
US4916134A (en) 4-[4-[4-[4-[[2-(2,4-difluorophenyl)-2-(1H-azolylmethyl)-1,3-dioxolan-4-yl]me]phenyl]-1-piperazinyl]phenyl]triazolones
US4619931A (en) [[4-[4-(4-phenyl-1-piperazinyl)phenoxymethyl]-1,3-dioxolan-2-yl]methyl]-1H-imidazoles and 1H-1,2,4-triazoles
US4267179A (en) Heterocyclic derivatives of (4-phenylpiperazin-1-yl-aryloxymethyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles
EP0283992B1 (en) 4-[4-[4-[4-[[2-(2,4-Difluorophenyl)-2-(1H-azolylmethyl)-1,3-dioxolan-4-yl]-methoxy]phenyl]-1-piperazinyl]phenyl]triazolones
US4287195A (en) Heterocyclic derivatives of [4-(piperazin-1-yl-phenyloxymethyl)-1,3-dioxolan-2-ylmethyl]-1H-imidazoles and 1H-1,2,4-triazoles
US4160841A (en) Heterocyclic derivatives of 1-(1,3-dioxolan-2-ylmethyl)-1H-imidazoles
EP0402989B1 (en) Antifungal 4-[4-[4-[4-[[2-(2,4-difluorophenyl)-2-(1H-azolylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl]phenyl]triazolones and imidazolones
US4402957A (en) Heterocyclic derivatives of [4-(piperazin-1-ylphenyloxymethyl)-1,3-dioxolan-2-ylmethyl]-1H-imidazoles and 1H-1,2,4-triazoles
US4490530A (en) Heterocyclic derivatives of (4-phenylpiperazin-1-yl-aryloxymethyl-1,3-dioxolan-2-yl)-methyl-1H-imidazoles and 1H-1,2,4-triazoles
US4735942A (en) [[4-[4-(4-phenyl-1-piperazinyl)phenoxymethyl]-1,3-dioxolan-2-yl]-methyl]-1H-imidazoles and 1H-1,2,4-triazoles having antimicrobial properties
US4456605A (en) Heterocyclic derivatives of [4-(piperazin-1-yl-phenyloxymethyl)-1,3-dioxolan-2-ylmethyl]-1H-imidazoles and 1H-1,2,4-triazoles
US4861879A (en) [[4-[4-Phenyl-1-piperazinyl)phenoxymethyl]-1-3-dioxolan-2-yl]-methyl]-1H-imidazoles and 1H-1,2,4-triazoles
US4229581A (en) Hydrazine carboxamide derivatives of 1-(1,3-dioxolan-2-ylmethyl)-1H-imidazoles and 1H-1,2,4-triazoles
US4229460A (en) Heterocyclic derivatives of 1-(1,3-dioxolan-2-ylmethyl)-1H-1,2,4-triazoles having antifungal and antibacterial properties
US4268680A (en) Heterocyclic derivatives of 1-(1,3-dioxolan-2-ylmethyl)-1H-imidazoles and 1H-1,2,4-triazoles
US4232034A (en) Heterocyclic derivatives of 1-(1,3-dioxolan-2-ylmethyl)-1H-imidazoles
KR820001889B1 (ko) (4-페닐피페라진-1-일-아릴옥시메틸-1, 3-디옥소란-2-일)-메틸-1h-이미다졸 및 1h-1, 2, 4-트리아졸의 새로운 헤테로싸이클 유도체의 제조방법

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE ES FR GB GR IT LI LU NL SE

17P Request for examination filed

Effective date: 19870813

17Q First examination report despatched

Effective date: 19890510

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

ITF It: translation for a ep patent filed
AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE ES FR GB GR IT LI LU NL SE

REF Corresponds to:

Ref document number: 73799

Country of ref document: AT

Date of ref document: 19920415

Kind code of ref document: T

REF Corresponds to:

Ref document number: 3684431

Country of ref document: DE

Date of ref document: 19920423

ET Fr: translation filed
REG Reference to a national code

Ref country code: GR

Ref legal event code: FG4A

Free format text: 3004114

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2032381

Country of ref document: ES

Kind code of ref document: T3

26N No opposition filed
EPTA Lu: last paid annual fee
EAL Se: european patent in force in sweden

Ref document number: 86202230.8

REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20020822

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20021204

Year of fee payment: 17

Ref country code: GB

Payment date: 20021204

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20021210

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20021211

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20021212

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20021216

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20021217

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20021220

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20021227

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20030121

Year of fee payment: 17

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20031210

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20031210

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20031210

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20031211

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20031211

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20031231

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20031231

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20031231

BERE Be: lapsed

Owner name: *JANSSEN PHARMACEUTICA N.V.

Effective date: 20031231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040701

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040701

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040705

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20031210

EUG Se: european patent has lapsed
REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040831

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee

Effective date: 20040701

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20031211

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.

Effective date: 20051210